Cargando…

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium.glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosano, Giuseppe, Quek, David, Martínez, Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2020
Materias:	Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689869/ https://www.ncbi.nlm.nih.gov/pubmed/33294215 http://dx.doi.org/10.15420/cfr.2020.23

Ejemplares similares

Clinical importance of urinary sodium excretion in acute heart failure
por: Damman, Kevin, et al.
Publicado: (2020)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Pulmonary Embolism and Heart Failure: A Reappraisal
por: Arrigo, Mattia, et al.
Publicado: (2021)

The Future of Telemedicine in the Management of Heart Failure Patients
por: Silva-Cardoso, José, et al.
Publicado: (2021)

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
por: Anker, Stefan D., et al.
Publicado: (2015)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
por: Angelini, Gianmarco, et al.
Publicado: (2021)

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
por: Iguchi, Moritake, et al.
Publicado: (2023)

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Which patients with heart failure should receive specialist palliative care?
por: Campbell, Ross T., et al.
Publicado: (2018)

Unequitable Heart Failure Therapy for Black, Hispanic and American-Indian Patients
por: Ilonze, Onyedika, et al.
Publicado: (2022)

Why Do so Few People with Heart Failure Receive Cardiac Rehabilitation?
por: Thompson, David R, et al.
Publicado: (2022)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Remote Patient Monitoring for Patients with Heart Failure: Sex- and Race-based Disparities and Opportunities
por: Mastoris, Ioannis, et al.
Publicado: (2023)

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians
por: Monzo, Luca, et al.
Publicado: (2023)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
por: Joshi, Shruti S, et al.
Publicado: (2021)

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial
por: Düngen, Hans-Dirk, et al.
Publicado: (2011)

In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction
por: Cox, Zachary L, et al.
Publicado: (2022)

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
por: Cohen-Solal, Alain, et al.
Publicado: (2009)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Correction: Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Publicado: (2021)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
por: Oh, Jaewon, et al.
Publicado: (2021)

Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
por: Moady, Gassan, et al.
Publicado: (2023)

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
por: Brownell, Nicholas K, et al.
Publicado: (2021)

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J V, et al.
Publicado: (2014)

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
por: Parthasarathy, Hari K., et al.
Publicado: (2009)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure
por: Rossignol, Patrick, et al.
Publicado: (2020)

Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients
por: Katic, Josip, et al.
Publicado: (2023)

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
por: Alkagiet, Stelina, et al.
Publicado: (2020)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022)

Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials
por: Kato, Eri Toda, et al.
Publicado: (2020)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
por: Shen, Xizi, et al.
Publicado: (2022)

Management protocols for chronic heart failure in India
por: Mishra, S., et al.
Publicado: (2018)

Mechanical Circulatory Support for Right Ventricular Failure
por: DeFilippis, Ersilia M, et al.
Publicado: (2022)

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
por: Strand, Vibeke
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dd50gs8b3qv2pcnlt2kcgoing1